MorphoSys(MOR) - 2021 Q4 - Annual Report

2 0 2 1 A n n u a l R e p o r t A n n u a l R e p o r t 2 0 2 1 Our Clinical Pipeline | | development stage | | --- | --- | | Program | | | Indication | | | Tafasitamab1 | | | L-MIND / Relapsed or refractory (r/r) | | | diffuse large B-cell lymphoma (DLBCL) | | | B-MIND / r/r DLBCL | | | firstMIND / First-line DLBCL | .00 0 | | frontMIND / First-line DLBCL | | | inMIND / r/r follicular lymphoma/ | | | marginal zone lymphoma | | | Pelabresib | | | MANIFEST-2 / Myelofibrosis | | | MANIFEST / Myelofibrosis | | ...